Contemporary research has upgraded angiogenesis as one of the hallmarks of cancer [14] and has led to the development of pharmacological anti-angiogenetic agents, primarily through the blockage of VEGF/VEGFR signaling [54]. This evidence concerns the gene VEGFA and cancer.